In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.

Direct-to-Patient (DTP) models are transforming how medications reach patients, moving beyond clinical research into commercial distribution. Originally developed to help rare disease trial participants avoid long travel to research sites, DTP has become a standard solution for improving patient access and convenience. Today, patients can receive small molecules, complex biologics, and even medical devices directly at home, making what was once exceptional now routine. Despite the benefits, D...

Send us a text It doesn't take a great imagination to see that Bovine Papillomavirus (BPV) is not pretty. And, in terms of cost to the animal producer - both Beef and Dairy - BPV is downright ugly. In this brief, to-the-point podcast, topical expert (and industry pro) Dr Bob Gentry explains BPV's startling affect on animal and herd health. Edited May, 2025 - 03:07 minutes #papillomavirus #cattlefarm #dairyfarm #animalhealth #veterinary #veterinarian ©VST Labs for Medgene www.MedgeneLabs.com ...

It’s back — the same conversations you loved, with a new name.Vigilance Unplugged explores the real stories behind careers in safety and risk management — and asks what’s next for the world of vigilance and life sciences.

In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.

In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.

This episode explores how different cultures around the world understand and interpret dreams. While modern science views dreams as brain activity, many ancient and traditional societies see them as messages from gods, ancestors, or spiritual realms.Aboriginal Australians connect dreams to Dreamtime, a sacred realm of creation. Native American tribes treat dreams as guides, using symbols like dreamcatchers for protection. African cultures such as the Zulu view dreams as communication from

The third Connecticut Genetic Counselors' Association (CTGCA) Annual Educational Conference was held last Friday (September 25th, 2025) at the gorgeous Jackson Laboratory for Genomic Medicine in Farmington, Connecticut. Our host Kira Dineen resides in Connecticut and has been lucky enough to present every year. This time moderating a panel about the economics of genetic counseling, which is now shared as this podcast episode. This panel conversation explores the economics of genetic

This week’s tHEORetically Speaking News Roundup covers nirsevimab’s real-world success in reducing RSV hospitalizations among infants, Boehringer Ingelheim’s FDA approval of Jascayd for idiopathic pulmonary fibrosis, and Arthrosi Therapeutics’ $153 million raise to advance a next-generation gout drug. We also highlight this year’s Nobel Prize in Medicine, honoring discoveries in immune tolerance that continue to shape today’s biggest breakthroughs. Tune in for this concise recap of these pivo...

Introduction to the Amoeba After Dark podcast

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.